SWISF - New to The Street Announces Episode 576 Four Business Guest Interviews Airs on Bloomberg TV as Sponsored Programming Tonight Thursday June 6 2024 at 9:30 PM PT | Benzinga
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national business TV show airing on Bloomberg TV as sponsored programming tonight, Thursday, June 6, 2024, at 9:30 PM PT.
New to The Street's TV episode 576 will air the following four (4) business interviews:
1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) () interview with David Luci, President/CEO.
2). Real Estate - La Rosa Holdings Corp's. (NASDAQ:LRHC) () interviews with Joe La Rosa, Founder and CEO, and José Couverte, Team Leader & Talent Acquisition Advisor.
3). "Game Changers" segment interview with Greene Concepts, Inc.'s (OTCMarkets: INKW) () Lenny Greene, CEO and President.
4). "Sekur Privacy & Sekur Security – The Weekly Hack" segment with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) () (Sekur®).
Episode 576
New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) () ("Company"), a late-stage biopharmaceutical Company. ACXP is developing a new class of small molecular antibiotics for life-threatening bacterial infections. With the successful completion of Phase 2 clinical trials on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI), management met with the FDA to map out a pathway for a full FDA drug approval. David tells viewers that the meeting was successful and that the FDA and ACXP agreed on a Phase 3 clinical trial protocol. Once fully approved, the Company will have the opportunity to pursue worldwide partnerships and revenue-streaming agreements. Over the next couple of years, David and the ACXP team expect a successful Phase 3 trial with full FDA approval. ACXP believes Ibezapolstat could be a market worth over $1B. As such, its shareholder base and stock prices could greatly benefit once the regulatory agencies in the USA and internationally approve the drug. Clinical data to date on completed trials have shown that the Ibezapolstat drug effectively treats CDI with no reinfections. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.
Joe La Rosa, Founder and CEO, and José Couverte, Team Leader & Talent Acquisition Advisor of La Rosa Holdings Corp. (NASDAQ:LRHC) () ("La Rosa") ("Company") are at the Nasdaq MarketSite Studio with New to The Street's TV Host Jane King. La Rosa Holdings Corp. is significantly disrupting the legacy business model in the real estate industry. With a proprietary technology platform incorporating AI, the Company can offer real-estate agents a choice in pay-out models, such as revenue-share or annual fee base. Because La Rosa Realty is agent-centric, offering agents 100% commissions and multiple revenue streams. Joe talks about meeting José, and immediately, they realize the existing synergies. José built and attracted around 14,000 agents for another company. José explains his vision for future ongoing successes at La Rosa while utilizing its AI technology platform. Even though La Rosa didn't innovate the 100% commission idea, La Rosa is doing it better while disrupting competing real-estate agencies and offering agents choices and multiple revenue streams. La Rosa Holdings Corp. has a work culture centered on its people; this is why La Rosa Holdings Corp. is a growing leader in the real estate industry sector. The on-screen QR code is available during the show; download or visit La Rosa Holdings Corp. - https://larosaholdings.com/.
New to The Street airs its "Game Changers" segment with TV Host Ana Berry, who talks with Lenny Greene, ...